Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Google Scholar citation report
Citations : 1556

Journal of Pain & Relief received 1556 citations as per Google Scholar report

Journal of Pain & Relief peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Open J Gate
  • Genamics JournalSeek
  • Cosmos IF
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
Share This Page

ADX-102, a novel aldehyde trap, reduces nociceptive behavior in mouse models of carrageenan and CFA induced pain

International Conference on Pain Research & Management

Susan Macdonald, Valerie Cullen, Todd Brady, Isaac Levi, Sigal Meilin and Scott Young

Aldeyra Therapeutics, USA MD Biosciences Inc., USA

Posters & Accepted Abstracts: J Pain Relief

DOI: 10.4172/2167-0846.C1.012

Abstract
A variety of aldehyde species have been shown to activate ion channels, such as TRPA1 and TRPV1, involved in mediating pain. Furthermore, aldehyde dehydrogenase 2 which diminishes aldehyde loads by oxidizing aldehydes to acids has been shown to modulate acute inflammatory pain in animal models. Thus, aldehyde signaling represents a novel therapeutic target for the treatment of pain. ADX-102 is a novel small molecule that covalently binds aldehydes including malondialdehyde and 4-hydroxynonenal, which have been shown to mediate inflammatory pain. For that reason, the effect of ADX-102 on acute inflammatory pain was tested in the carrageenan-induced and Complete Freund�s Adjuvant (CFA)-induced models in mice. ADX-102 was administered intraperitoneally prior to and after pain induction, at different doses and schedules (30 mg/kg twice daily [BID], 100 mg/kg once daily [QD], or 100 mg/kg BID). Thermal hypersensitivity, mechanical hypersensitivity and paw swelling were assessed at various times to explore the effect of modulating aldehyde signaling on different molecular mechanisms underlying pain. Diclofenac was used as a positive control and vehicle was used as a negative control. ADX-102 mediated dose-dependent reductions in nociceptive behavior in both models of acute pain. In the CFA model, treatment with 100 mg/kg QD or 100 mg/kg BID ADX-102 resulted in statistically significant reductions in thermal hypersensitivity, but reduced mechanical hypersensitivity only after treatment with 100 mg/kg ADX-102 BID. In the carrageenan model, ADX-102 treatment resulted in statistically significant reductions in thermal hypersensitivity at ADX-102 doses of 30 mg/kg BID and 100 mg/kg BID, but did not affect mechanical hypersensitivity. Minor effects on paw swelling were observed in both models. The data imply that ADX-102 may differentially affect thermal and mechanical pain pathways. Overall, the results support the role of aldehyde signaling in pain and suggest that aldehyde traps represent a novel approach for the treatment of pain.
Biography

Susan Macdonald received her PhD from the University of Massachusetts Medical School and did Post-doctoral work at Onyx Pharmaceuticals. She has extensive experience in Research and Development in the biopharmaceutical industry and is currently Vice President of Research and Development at Aldeyra Therapeutics, a biotechnology company developing a proprietary family of aldehyde traps, which sequester and allow for the degradation of toxic aldehydes, and thus have broad therapeutic potential. She has published numerous articles and book chapters.

Email: smacdonald@aldeyra.com

Relevant Topics
Top